Law and Regulations

This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

The 4 key organizations regularly focusing on respiratory virus season released updated vaccine recommendations for 2026-2027.

The American Pharmacists Association, Canadian Pharmacists Association, and International Pharmaceutical Federation release plans for pharmacists’ primary care integration.

The federal government is actively looking to enhance its evolving approach toward US childhood vaccine recommendations.

Heidi Overton, MD, PhD, was nominated to the position amid debates on abortion pill access, childhood immunization schedules, and more.

Hailey Choi, PharmD, BCAC, CDCES, Jana Murry, PharmD, RPh, and Spencer Casella, PharmD, RPh, answer key questions on GLP-1 compounding.

This episode provides a detailed breakdown of the CVS Caremark-FTC settlement from July, exploring a shifting landscape of pharmacy benefit management.

The year 2026 has brought a stark paradox to American pharmacy practice, and it’s affecting the most sought-after prescription drugs on the market.

The pharmacy benefits industry is undergoing a massive restructuring, driven by a wave of government action designed to shift focus back to the patient.

In part 2, McMahan contextualizes the recent FTC-Caremark settlement with some of the industry’s major reform efforts in recent history.

Based on discussions from a recent webinar debate on the 340B Drug Pricing Program, we’re revealing how differently key stakeholders see a program that pharmacists participate in every day.

Tom Kraus, JD, of ASHP, and Shawn Gremminger, MPP, of the National Alliance of Healthcare Purchaser Coalitions, face off on the 340B Drug Pricing Program.

This episode explores PBMs’ copay collection discrepancies and how improper documentation can be the downfall for pharmacy business.

The major retail entity owns and operates pharmacies across many grocery stores, including Giant, Stop & Shop, Food Lion, and more.

This episode highlights the FDA’s announcement regarding GLP-1 supply stabilization and critical compliance strategies for 503A pharmacies.

As PBM-pharmacy relationships evolve in real time, staying proactive when a PBM audit comes through could be the difference between thriving and losing essential business.

Federal court blocks abrupt childhood vaccine schedule changes, raising insurance and liability uncertainty as pharmacies navigate shifting guidance and growing parent hesitancy.

Represented by Frier Levitt, multiple hospital systems filed lawsuits on May 21, 2026, targeting a variety of entities existing under CVS Health.

From supporting MTM services to reaching unhoused populations, the 340B program is a powerhouse for patient care, access, and affordability.

As debates heat up between anti-abortion and pro-life advocates, the federal government places a hold on any action toward mifepristone’s approval.